We are live on ! Find out more
FBIOP icon

Fortress Biotech 9.375% Series A Preferred Stock
FBIOP

3 hedge funds and large institutions have $5.72M invested in Fortress Biotech 9.375% Series A Preferred Stock in 2020 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more capital invested

Capital invested by funds: $5.26M → $5.72M (+$462K)

0% more funds holding

Funds holding: 3 → 3 (0)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

1.88% less ownership

Funds ownership: 10.91% → 9.03% (-1.9%)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SAM
Shikiar Asset Management
New York
+$408K

Top Sellers

Rank Fund Capital Flow
1
UIC
Uniplan Investment Counsel
Wisconsin
-$246K
Name Holding Trade Value Shares
Change 		Change in
Stake
UIC
1
Uniplan Investment Counsel
Wisconsin
$3.75M -$246K -13,368 -6%
SAM
2
Shikiar Asset Management
New York
$1.97M +$408K +22,200 +27%
PCG
3
Private Capital Group
Connecticut
$3K – – –

FBIOP Hedge Fund Activity: Q3 2020 in Review

3 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) for Q3 2020, worth a combined $5.72M — up 8.8% from $5.26M a quarter earlier.

Fund positioning in FBIOP was balanced in Q3 2020: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Shikiar Asset Management, adding an estimated $408K. The largest seller was Uniplan Investment Counsel, cutting an estimated $246K.

  • 3 institutional investors held Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) as of Q3 2020, unchanged from Q2 2020.
  • Funds reported $5.72M of Fortress Biotech 9.375% Series A Preferred Stock stock for Q3 2020, up 8.8% quarter-over-quarter.
  • 0 funds opened new Fortress Biotech 9.375% Series A Preferred Stock positions in Q3 2020 and 0 closed out.
  • The largest Fortress Biotech 9.375% Series A Preferred Stock buyer in Q3 2020 was Shikiar Asset Management, an estimated $408K added.
  • The largest Fortress Biotech 9.375% Series A Preferred Stock seller in Q3 2020 was Uniplan Investment Counsel, an estimated $246K sold.

Based on aggregated 13F filings for Q3 2020.